A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours

To assess tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and clinical activity of the dual epidermal growth factor receptor (EGFR) 1 and 2 (HER2) tyrosine kinase inhibitor BIBW 2992. An escalating schedule of once-daily (OD) BIBW 2992 for 14 days followed by 14 days off medication was ex...

Descripción completa

Detalles Bibliográficos
Autores principales: Eskens, F A L M, Mom, C H, Planting, A S T, Gietema, J A, Amelsberg, A, Huisman, H, van Doorn, L, Burger, H, Stopfer, P, Verweij, J, de Vries, E G E
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2008
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2359721/
https://www.ncbi.nlm.nih.gov/pubmed/18026190
http://dx.doi.org/10.1038/sj.bjc.6604108

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2359721/
https://www.ncbi.nlm.nih.gov/pubmed/18026190
http://dx.doi.org/10.1038/sj.bjc.6604108

Ejemplares similares